02:15 PM EST - Abattis Bioceuticals Corp. : Announced the pending release of “Comfort”, a nutraceutical designed to target chronic pain and inflammation. As previously announced, the Company hopes to launch Comfort on Cyber Monday through the Company’s wholly-owned subsidiary, Vergence Naturals Ltd. Abattis and Vergence unveil “Comfort” a new product line targeting Chronic Pain & Inflammation. Abattis Bioceuticals Corp.
shares ATT:CNX are trading up 2.86 percent at $0.18.
